508 related articles for article (PubMed ID: 17894650)
1. Catechol-O-methyltransferase and its inhibitors in Parkinson's disease.
Bonifácio MJ; Palma PN; Almeida L; Soares-da-Silva P
CNS Drug Rev; 2007; 13(3):352-79. PubMed ID: 17894650
[TBL] [Abstract][Full Text] [Related]
2. Catechol-O-methyltransferase and Parkinson's disease.
Tai CH; Wu RM
Acta Med Okayama; 2002 Feb; 56(1):1-6. PubMed ID: 11873938
[TBL] [Abstract][Full Text] [Related]
3. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
Müller T
Drugs; 2015 Feb; 75(2):157-74. PubMed ID: 25559423
[TBL] [Abstract][Full Text] [Related]
4. COMT inhibition in the treatment of Parkinson's disease.
Ruottinen HM; Rinne UK
J Neurol; 1998 Nov; 245(11 Suppl 3):P25-34. PubMed ID: 9808337
[TBL] [Abstract][Full Text] [Related]
5. New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease.
Bonifati V; Meco G
Pharmacol Ther; 1999 Jan; 81(1):1-36. PubMed ID: 10051176
[TBL] [Abstract][Full Text] [Related]
6. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
Engelbrecht I; Petzer JP; Petzer A
Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
[TBL] [Abstract][Full Text] [Related]
7. New pharmacotherapy for Parkinson's disease.
Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice.
Marsala SZ; Gioulis M; Ceravolo R; Tinazzi M
Clin Neuropharmacol; 2012; 35(4):185-90. PubMed ID: 22805229
[TBL] [Abstract][Full Text] [Related]
9. Cheminformatics and virtual screening studies of COMT inhibitors as potential Parkinson's disease therapeutics.
Moschovou K; Melagraki G; Mavromoustakos T; Zacharia LC; Afantitis A
Expert Opin Drug Discov; 2020 Jan; 15(1):53-62. PubMed ID: 31744341
[No Abstract] [Full Text] [Related]
10. Influence of COMT inhibition on levodopa pharmacology and therapy.
Goetz CG
Neurology; 1998 May; 50(5 Suppl 5):S26-30. PubMed ID: 9591519
[TBL] [Abstract][Full Text] [Related]
11. Extending levodopa action: COMT inhibition.
Martínez-Martín P; O'Brien CF
Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
[TBL] [Abstract][Full Text] [Related]
12. Bioanalytical chromatographic methods for the determination of catechol-O-methyltransferase inhibitors in rodents and human samples: a review.
Gonçalves D; Alves G; Soares-da-Silva P; Falcão A
Anal Chim Acta; 2012 Jan; 710():17-32. PubMed ID: 22123108
[TBL] [Abstract][Full Text] [Related]
13. Clinical advantages of COMT inhibition with entacapone - a review.
Gordin A; Kaakkola S; Teräväinen H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1343-63. PubMed ID: 15340869
[TBL] [Abstract][Full Text] [Related]
14. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease.
Ceravolo R; Piccini P; Bailey DL; Jorga KM; Bryson H; Brooks DJ
Synapse; 2002 Mar; 43(3):201-7. PubMed ID: 11793426
[TBL] [Abstract][Full Text] [Related]
15. COMT inhibitors in Parkinson's disease.
Rivest J; Barclay CL; Suchowersky O
Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S34-8. PubMed ID: 10451758
[TBL] [Abstract][Full Text] [Related]
16. Entacapone in the management of Parkinson's disease.
Henchcliffe C; Waters C
Expert Opin Pharmacother; 2002 Jul; 3(7):957-63. PubMed ID: 12083995
[TBL] [Abstract][Full Text] [Related]
17. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
Kaakkola S
Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464
[TBL] [Abstract][Full Text] [Related]
18. COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?
Olanow CW; Stocchi F
Neurology; 2004 Jan; 62(1 Suppl 1):S72-81. PubMed ID: 14718683
[TBL] [Abstract][Full Text] [Related]
19. Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease.
Guay DR
Pharmacotherapy; 1999 Jan; 19(1):6-20. PubMed ID: 9917075
[TBL] [Abstract][Full Text] [Related]
20. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
Ferreira JJ; Almeida L; Cunha L; Ticmeanu M; Rosa MM; Januário C; Mitu CE; Coelho M; Correia-Guedes L; Morgadinho A; Nunes T; Wright LC; Falcão A; Sampaio C; Soares-da-Silva P
Clin Neuropharmacol; 2008; 31(1):2-18. PubMed ID: 18303486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
